Appendix Table 2a.
Baseline Demographics Based on Availability of Follow-Up
| Demographic | With Follow-Up Questionnaire | Without Follow-Up questionnaire | p-value* |
|---|---|---|---|
| All | 1474 | 922 | |
| Sex | |||
| Male | 766 (51.97%) | 476 (51.63%) | NS |
| Female | 708 (48.03%) | 446 (48.37%) | |
| Race/Ethnicity | |||
| Caucasian | 1130 (76.66%) | 658 (71.37%) | 0.02 |
| Latino | 60 (4.07%) | 47 (5.10%) | |
| African American | 171 (11.60%) | 115 (12.47%) | |
| Asian | 39 (2.65%) | 41 (4.45%) | |
| Other | 74 (5.02%) | 61 (6.62%) | |
| Age | |||
| <=54 | 204 (13.84%) | 149 (16.16%) | 0.002 |
| 55-59 | 169 (11.47%) | 136 (14.75%) | |
| 60-64 | 237 (16.08%) | 122 (13.23%) | |
| 65-69 | 276 (18.72%) | 134 (14.53%) | |
| 70-74 | 242 (16.42%) | 161 (17.46%) | |
| 75-79 | 210 (14.25%) | 113 (12.26%) | |
| 80+ | 136 (9.23%) | 107 (11.61%) | |
| Stage | |||
| I | 617 (41.86%) | 133 (14.43%) | <0.0001 |
| II | 150 (10.18%) | 82 (8.89%) | |
| III | 390 (26.46%) | 259 (28.09%) | |
| IV | 250 (16.96%) | 378 (41.00%) | |
| Unknown/Missing | 67 (4.55%) | 70 (7.59%) | |
| Histology | |||
| NSCLC | 1296 (87.92%) | 729 (79.07%) | NS |
| SCLC | 115 (7.80%) | 149 (16.16%) | |
| Missing | 63 (4.27%) | 44 (4.77%) | |
| Treatment | <0.0001 | ||
| Surgery | 470 (31.87%) | 93 (10.09%) | |
| Chemotherapy | 159 (10.79%) | 199 (21.58%) | |
| Radiotherapy | 46 (3.12%) | 80 (8.68%) | |
| Surgery w/Chemotherapy | 211 (14.31%) | 60 (6.51%) | |
| Surgery w/Radiotherapy | 46 (3.12%) | 17 (1.84%) | |
| Chemoradiotherapy | 331 (22.46%) | 348 (37.74%) | |
| Surgery w/Chemo/Rad | 141 (9.57%) | 66 (7.16%) | |
| No Treatment | 70 (4.75%) | 59 (6.40%) | |
| Comorbidity | NS | ||
| None | 263 (17.84%) | 150 (16.27%) | |
| Mild | 487 (33.04%) | 257 (27.87%) | |
| Moderate | 268 (18.18%) | 144 (15.61%) | |
| Severe | 222 (15.06%) | 153 (16.59%) | |
| Unknown/Missing | 234 (15.88%) | 218 (23.64%) |
*
χ2 test. NS, not significant.